# Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients

> **NCT00730925** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 41 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** BIBW2992
- **DRUG:** BIBW2992 + paclitaxel

## Key facts

- **NCT ID:** NCT00730925
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2012-01
- **Final completion:** —
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2014-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00730925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00730925, "Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00730925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*